XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.3
COLLABORATION AND LICENSING AGREEMENTS - Narrative (Details)
$ in Thousands, $ in Millions, ¥ in Billions
 1 Months Ended 3 Months Ended 9 Months Ended 77 Months Ended
Dec. 31, 2017
USD ($)
Nov. 30, 2017
USD ($)
Jun. 30, 2015
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2024
CAD ($)
Sep. 30, 2023
USD ($)
Mar. 31, 2024
USD ($)
Sep. 30, 2024
JPY (¥)
Oct. 31, 2023
USD ($)
Jul. 31, 2023
USD ($)
Oct. 31, 2022
USD ($)
Apr. 30, 2022
USD ($)
payment_tranche
Mar. 31, 2018
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenues       $ 98,241 $ 56,391 $ 217,486   $ 90,093              
Licensing revenue                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenues       20 32,014 56   32,790              
Non-cash royalty revenue related to the sale of future royalties                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenues       809 0 1,776   0              
Product supply revenue                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenues       5,322 2,092 7,461   5,354              
2017 KKC Agreement | Non-cash royalty revenue related to the sale of future royalties                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenues       800   1,800                  
2017 KKC Agreement | Product supply revenue                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenues       5,300 2,100 7,500   5,400              
Fosun Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenues       0   0                  
Fosun Agreement | Licensing revenue                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenues         2,000     2,000              
Knight Agreement | Licensing revenue                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Total revenues       0 0 0   0              
KKC | 2017 KKC Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Upfront license fees   $ 30,000                          
Potential development milestones   $ 55,000                          
Total revenues                 $ 35,000            
Potential commercialization milestones       59,800   59,800       ¥ 8.5          
Fee receivable for reduction in royalty rate                           $ 40,000  
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche                           2  
KKC | 2017 KKC Agreement | Licensing revenue                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Proceeds from milestone payments         30,000     30,000         $ 35,000    
Fosun Pharma | Fosun Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Proceeds from milestone payments       8,000   8,000         $ 3,000 $ 2,000      
Upfront payment received $ 12,000                            
Potential development and commercialization milestones           $ 113,000                  
Threshold percentage of net sales for tiered royalties           20.00% 20.00%                
Knight | Knight Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Potential development milestones       700   $ 700                  
Non-cash royalty revenue                             $ 2,300
Potential development and commercialization milestones           16,400 $ 22.2                
AstraZeneca | AZ Termination Agreement                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Percentage of royalty revenue     10.00%                        
Percentage of non-royalty revenue     20.00%                        
Maximum potential payment per agreement     $ 75,000                        
Aggregate cost of revenue recognized       50,300   50,300                  
Cost of revenue       $ 10,000 $ 5,700 $ 22,700   $ 8,700